What your monthly recap looks like.

You moved from 5 mg to 7.5 mg in week 13 and held through the full month. Weight came down 4.2 lb against a goal pace of 3.5 — slightly ahead. Appetite scored 2/5 fewer days, side effects half what they were on the dose-up week, journal entries on day-after-shot showed the trough timing has shifted earlier (Tuesdays now, was Wednesdays at 5 mg).

This is the dose-finding window. Don't go up to 10 mg yet — there's another month of useful titration response still hiding in the 7.5 mg curve. Your fullness scores haven't plateaued.

Your trend slope steepened from −0.71 lb/wk on 5 mg to −0.96 lb/wk after the step-up — the kind of inflection that confirms the dose change is doing useful work.

SHOTS LOGGED

4 of 4Sundays

WEIGH-INS

22 of 2879% · skipped 3 weekends

JOURNAL ENTRIES

11avg 2.75/week

SYMPTOM LOGS

7all minor (nausea ≤2)

Week 13 (dose-up week) showed expected breakthrough nausea on Mon + Tue — both rated 2/5, both resolved by Wednesday evening. No reports in weeks 14–16. No gallbladder symptoms, no constipation flags, no early satiety beyond expected.

Plus pulls the journal text alongside the symptom score so the prescriber sees context, not just numbers. Sample entry from your Wk 13 Tuesday: “Skipped breakfast, tried plain toast at 11, kept it down. Hydration helped.”

A1C

5.6 %down from 5.8 (Jan)

FASTING GLUCOSE

94 mg/dL+0 from last quarter

TOTAL CHOLESTEROL

198 mg/dL−12 from baseline

LDL

108 mg/dLwithin ±5

TRIGLYCERIDES

134 mg/dL−18 from baseline

RESTING HEART RATE

68 bpm−4 from baseline

The A1C drop is well within the expected tirzepatide range for your starting profile. Triglycerides moving in tandem with weight is the pattern you want — confirms metabolic response, not just scale movement.

The model gives an off-ramp readiness score based on dose-response stability, weight trajectory predictability, and lab markers. Yours is currently 38 / 100 — well below the 75 threshold we treat as a starting point for a prescriber-led taper conversation.

Realistic earliest off-ramp window if you stay on 7.5 mg: October 2026. If you step up to 10 mg at month 5, that pushes to December 2026 (the model favors longer titration runs over rushed step-downs).

• Trough day timing. Your shift to Tuesday trough is normal at higher doses. If it slides further back (Monday), that's a signal the 7.5 mg dose is running out earlier than the weekly schedule — log it, we'll re-check next month.
• Resistance work. Plus only sees what you log; if you started lifting this month and didn't add it to the activity tab, the model is undercounting your lean-mass preservation signal. Worth backfilling.